Navigation Links
Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
Date:3/22/2012

GOTHENBURG, Sweden, March 22, 2012 /PRNewswire/ --

The new Dynaflow Resolve System was developed in close collaboration with leading ion-channel research groups to meet the demand for a simpler technology capable of complex perfusion protocols. The Dynaflow Resolve System is an advanced automated perfusion system that enables novel experimental protocols by allowing recording of any ion channel current, using any cell type, and any compound. The new and improved system retains all the advantages from the previously validated Dynaflow technology and now features the Resolve Glass Chip, providing reusability and adsorption-free perfusion.

"We are very impressed and happy with the data quality the Dynaflow Resolve Glass Chip is providing, both from cell lines and acutely isolated striatal neurons." says Ari-Pekka Koivisto, PhD, Orion Pharma, Finland.

The Dynaflow Resolve chip is made out of glass and has been developed based on customer requirements to minimize adsorption of highly hydrophobic compounds. Besides complete experimental freedom the chip offers reusability and improved cost-efficiency.

"The Dynaflow Resolve chip has solved our problems with difficult compounds and also offers complete flexibility well controlled perfusion and reusability with easy cleaning." Jessica Strömberg, PhD, Umecrine, Umeå, Sweden.

With the launch of the improved Dynaflow Resolve Glass Chip and System, Cellectricon will discontinue the production of the disposable plastic chips by the end of June 2012. Cellectricon offers new and existing customers the ability to take advantage of the benefits of this new technology.

About Cellectricon

Cellectricon, is a leading provider of advanced compound screening technologies and services to accelerate drug discovery and cell-based assay research. Our proprietary technologies include leading systems for high resolution ion-channel screening and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess® Technology enables scalable  field stimulation, compound delivery and transfection for genomic screening of primary cells, neurones and stem cells. The Dynaflow® Technology advances ion channel research and discovery applications.

http://www.cellectricon.com


'/>"/>
SOURCE Cellectricon
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
2. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
3. Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. David Burns Appointed CEO/President of Cellectricon
6. Hooper Holmes Heritage Labs Division Launches New Home Diabetes Test
7. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
8. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
9. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
10. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
11. ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... MiMedx Group, Inc. (NASDAQ: MDXG), the leading ... allografts and patent-protected processes to develop and market advanced ... today  that it will present at the Needham Healthcare ... Parker H. "Pete" Petit, Chairman and CEO, Michael ... Cashman , EVP and Chief Commercialization Officer, and ...
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... Md. , March 23, 2017  Northwest ... developing DCVax® personalized immune therapies for solid tumor ... the $7.5 million financing it announced last Friday, ... sold to several institutional investors securities totaling 28,843,692 ... per share, and 10,000,000 shares of Class C ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
Breaking Biology News(10 mins):